Clinical Testing News and Research

RSS

KMI receives 2-year Phase II SBIR grant to study new treatment for TBI

Kinetic Muscles Inc., a leading innovator of neurorehabilitation technology, announced it has received a 2-year Phase II SBIR grant to study a new treatment for veterans returning from active duty with traumatic brain injury.

5 Apr 2010

DNA patent case: US District Judge rules in favor of AMP

The Association for Molecular Pathology (AMP) is an international medical and professional association representing approximately 1,800 physicians, doctoral scientists, and medical laboratory scientists who perform laboratory testing based on knowledge derived from molecular biology, genetics, and genomics. AMP applauds US District Judge Robert Sweet's ruling in favor of the plaintiffs in the lawsuit, Association for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al.

2 Apr 2010

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.

29 Mar 2010

AGA Medical gets IDE approval to evaluate AMPLATZER Cardiac Plug

AGA Medical Holdings, Inc. today announced it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to evaluate the safety and efficacy of its AMPLATZER® Cardiac Plug, or ACP, to close the left atrial appendage.

25 Mar 2010

Evotec AG reports financial results and corporate updates for 2009

Based on the Action Plan 2012, Evotec decided in March 2009 to strengthen its discovery alliances, creating the central vehicle for growth, and to implement strict cost cutting and restructuring measures. The Company reduced headcount in administrative and clinical development functions, reprioritised its R&D activities, concentrated its operations in Europe and closed the former facility of Renovis, Inc. in South San Francisco.

25 Mar 2010

Regado Biosciences announces first successful subcutaneous application of an aptamer

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.

15 Mar 2010

ATS releases new clinical policy statement on CCHS

The American Thoracic Society has released a new official clinical policy statement on congenital central hypoventilation syndrome (CCHS), a disorder of respiratory and autonomic nervous system (ANS) regulation. The ANS regulates reflexive acts, including heart rate and blood pressure, digestion, body temperature and pain perception.

15 Mar 2010

Development of promising new cancer therapies: OICR announces $1M investment

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced an investment of $1 million towards the development of two new promising cancer therapies.

12 Mar 2010

Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment

Affymax, Inc. today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize Hematide™, Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan.

10 Mar 2010

Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010

Helix BioPharma Corp. today announced financial results for the second quarter ended January 31, 2010.

10 Mar 2010

McGill, Enobia Pharma collaborate to develop treatments for serious genetic bone diseases

Dr. Marc McKee, of McGill's Faculty of Dentistry and the Department of Anatomy and Cell Biology, is collaborating closely with Enobia Pharma Inc, a Quebec biotech company, to develop innovative treatments for serious genetic bone diseases. McKee's research looks into the reasons why calcium-phosphate mineral fails to crystallize properly to form strong bones and teeth.

6 Mar 2010

Common allergens that may cause contact dermatitis

Itchy irritated skin can leave some people scratching their heads trying to determine the cause of this bothersome condition. What did they touch? Is it just dry skin gone awry? Are they allergic to something in their home or workplace? The answers to these questions could require not only a little detective work, but the help of a dermatologist who can diagnose and treat the most likely culprit - contact dermatitis.

5 Mar 2010

ZyGEM introduces new RNAGEM Tissue RNA extraction kits

ZyGEM Corp. Ltd., a provider of innovative enzyme-based products for DNA and RNA extraction and other life sciences applications, today announced the launch of its new RNAGEM™ Tissue RNA extraction kits. This product represents a significant advance in sample preparation for RNA-based testing and analysis.

2 Mar 2010

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Absorption Systems, a leader in testing drugs for ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity), has joined the Society of Toxicology, the premier global professional association of toxicologists, as an SOT Affiliate. The firm, a contract research organization, has more than a decade of experience assisting pharmaceutical and biotechnology companies in determining which compounds in development should be advanced into clinical testing.

27 Feb 2010

Eli Lilly, Covance announce key milestones of their first-year partnership

Senior executives from Eli Lilly and Company and Covance Inc. announced Friday that the first year of their landmark alliance has been a win-win for both companies, enabling Lilly to expedite the flow of innovation within its pipeline in order to provide improved outcomes for individual patients.

27 Feb 2010

Adolor announces $14.6M net product sales of ENTEREG for year ended December 31, 2009

Adolor Corporation today reported a net loss of $47.9 million, or $(1.03) per basic and diluted share, for the year ended December 31, 2009, compared to a net loss of $30.1 million, or $(0.65) per basic and diluted share, for the year ended December 31, 2008.

25 Feb 2010

PointCare Technologies donates rapid PointCare NOW tests to Haitian clinics

PointCare Technologies, pioneer inventor of a portable diagnostic system that enables effective HIV/AIDS monitoring for millions of people in remote areas of developing countries, has donated 4,000 (a month's supply) of its rapid PointCare NOW tests to Haitian clinics to ensure the resumption of critical care to HIV/AIDS patients.

24 Feb 2010

TB's mechanism to evade body's immune system identified

Indiana University School of Medicine researchers have identified a mechanism used by the tuberculosis bacterium to evade the body's immune system and have identified a compound that blocks the bacterium's ability to survive in the host, which could lead to new drugs to treat tuberculosis.

16 Feb 2010

Better and standardized animal models needed for musculoskeletal regenerative medicine

Clinical testing and development of novel therapies based on advances in tissue engineering and regenerative medicine that will one day enable the repair and replacement of diseased or damaged human muscle, bone, tendons, and ligaments depends on the availability of good animal models.

12 Feb 2010

iTech Medical signs manufacturing agreement with Thought Technology for MPR technology

iTech Medical, an information technology company, announced today that it has signed an exclusive, three-year manufacturing agreement with Thought Technology Ltd. of Montreal, Quebec for the Company’s proprietary Muscle Pattern Recognition (MPR) technology.